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Appropriate selection of 
convalescent plasma 
donors for COVID-19
We read with considerable interest 
the Comment from Long Chen and 
colleagues1 about the potential 
use of convalescent plasma for 
the treatment of COVID-19. Chen 
and colleagues mention the earlier 
pragmatic WHO recommendation 
for the use of con valescent plasma 
as therapy in Ebola virus disease.2 
The absence of a clinically relevant 
therapeutic benefit in patients with 
Ebola virus infection described by 
Griensven and colleagues,3 and more 
recently the finding of no therapeutic 
benefit in a small trial in patients 
with COVID-19 in Zhengzhou, 
China,4 will be used to question the 
usefulness of convalescent plasma 
in COVID-19. In the Guinea-Bissau 
Ebola study,3 no attempt was made 
to select donors for the potency of 
their neutralising antibody. In the 
COVID-19 study,4 seropositive donors 
were recruited only after IgM antibody 
to severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) was no 
longer detected, and no attempt to 
quantify the antibody response was 
reported. We previously described 
the levels of detectable antibody 
and the inferred level of neutralising 
antibody in convalescent plasma 
donors for patients with Ebola virus 
disease in Sierra Leone,5 showing 
100-fold differences in the level of 
neutralising antibody. We described a 
strategy for selecting donors with the 
highest levels of neutralising antibody, 
which was not undertaken in donors 
in the Guinea-Bissau or Zhengzhou 
studies. For planned interventions 
in the treatment of patients with 
COVID-19 severe disease, we strongly 
recommend selection and qualification 
only of donors who carry the highest 
levels of detectable neutralising 
antibody to SARS-CoV-2. In this 
respect, we have data which indicate 
that quantification of specific antibody 
to the receptor-binding domain 
will indicate levels of neutralising 
antibody (unpublished). Commercial 
assays based on the receptor-binding 
domain alone, although not intended 
for the purpose of identifying suitable 
convalescent plasma donors, will 
probably be able to serve this need.
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